UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

~~FORM~~SECURITIES ~~8-K~~AND EXCHANGE COMMISSION

~~CURRENT~~WASHINGTON, ~~REPORT~~D.C. 20549

~~Pursuant~~FORM ~~to Section 13 or 15(d) of the Securities Exchange Act of 1934~~8-K

~~Date~~CURRENT ~~of Report (Date of earliest event reported): October 14, 2025~~REPORT

~~SCYNEXIS,~~Pursuant ~~Inc.~~to Section 13 or 15(d)

~~(Exact name~~ of ~~Registrant~~the asSecurities ~~Specified~~Exchange inAct ~~Its~~of ~~Charter)~~1934

Delaware	001-36365	56-2181648
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
1 Evertrust Plaza13th Floor
Jersey City, New Jersey		07302-6548
(Address of Principal Executive Offices)		(Zip Code)

Date of Report (Date of earliest event reported): March 31, 2026

~~Registrant’s~~ ~~Telephone Number~~SCYNEXIS, ~~Including~~Inc. ~~Area Code: 201 884-5485~~

(~~Former~~Exact ~~Name~~name orof ~~Former~~Registrant ~~Address,~~as ifSpecified ~~Changed~~in ~~Since~~Its ~~Last Report~~Charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Delaware	001-36365	56-2181648
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1 Evertrust Plaza
13th Floor
Jersey City, New Jersey		07302-6548
(Address of Principal Executive Offices)		(Zip Code)

~~☐Written~~Registrant’s ~~communications~~Telephone ~~pursuant~~Number, toIncluding ~~Rule~~Area ~~425~~Code: ~~under~~201 ~~the Securities Act (17 CFR 230.425)~~884-5485

~~☐Soliciting~~(Former ~~material~~Name ~~pursuant~~or toFormer ~~Rule~~Address, ~~14a-12~~if ~~under~~Changed ~~the~~Since ~~Exchange~~Last ~~Act (17 CFR 240.14a-12~~Report)

~~☐Pre~~Check the appropriate box below if the Form 8-~~commencement~~K ~~communications~~filing ~~pursuant~~is intended to ~~Rule~~simultaneously ~~14d-2(b)~~satisfy ~~under~~the filing obligation of the ~~Exchange~~registrant ~~Act~~under ~~(17~~any ~~CFR~~of ~~240.14d-2(b))~~the following provisions:

☐~~Pre-commencement~~ Written communications pursuant to Rule ~~13e-4(c)~~425 under the ~~Exchange~~Securities Act (17 CFR ~~240~~230.~~13e-4(c~~425))

~~Securities~~☐ ~~registered~~Soliciting material pursuant to ~~Section~~Rule 14a-12~~(b)~~ ofunder the Exchange Act: (17 CFR 240.14a-12)

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		SCYX		The Nasdaq Global Market

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~Indicate~~☐ byPre-commencement ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405 of the Securities Act of 1933~~ 13e-4(~~§ 230.405 of this chapter~~c) orunder ~~Rule 12b-2 of~~ the ~~Securities~~ Exchange Act of(17 ~~1934~~CFR (§ 240.~~12b~~13e-~~2 of this chapter~~4(c). )

~~Emerging~~Securities ~~growth~~registered ~~company~~pursuant ☐to Section 12(b) of the Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	SCYX	The Nasdaq Capital Market

~~Item~~Indicate 1by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.01405 ~~Entry~~of ~~into~~this achapter) ~~Material~~or ~~Definitive~~Rule ~~Agreement~~12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

~~Binding~~Emerging ~~Memorandum~~growth ~~of Understanding for Amendment to Exclusive License Agreement with GSK~~company ☐

If Onan ~~October~~emerging ~~14,~~growth ~~2025~~company, ~~SCYNEXIS,~~indicate ~~Inc.~~by ~~(“SCYNEXIS”)~~check ~~and~~mark ~~GlaxoSmithKline~~if ~~Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (~~the ~~“Binding~~registrant ~~2025~~has ~~MOU”)~~elected ~~for~~not ~~amendment~~ to ~~the~~use ~~exclusive license agreement between SCYNEXIS and GSK, dated March 30, 2023, as amended by a binding memorandum of understanding on December 26, 2023 (~~the ~~“Binding~~extended ~~2023~~transition ~~MOU”)~~period ~~(the~~for ~~exclusive~~complying ~~license agreement and Binding 2023 MOU, together~~ with ~~the~~any ~~associated~~new ~~Transitional~~or ~~Manufacturing~~revised ~~and~~financial ~~Supply~~accounting ~~Agreement,~~standards ~~the~~provided ~~“Exclusive~~pursuant ~~License Agreement”). Pursuant~~ to ~~the terms of the Exclusive License Agreement, SCYNEXIS granted GSK an exclusive~~ Section 13(~~even as to SCYNEXIS and its affiliates~~a), ~~royalty-bearing, sublicensable license for the development, manufacture, and commercialization~~ of ~~ibrexafungerp, including~~ the approved product BREXAFEMME®, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties. The terms of the Exclusive License Agreement are further described in SCYNEXIS’s Current Reports on Form 8-K filed with the Securities and Exchange ~~Commission on March 30, 2023 and January 2, 2024~~Act. ☐

AsItem ~~previously disclosed, there was a disagreement between SCYNEXIS and GSK regarding the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis (the “MARIO Study”)~~7.01 ~~The~~Regulation ~~parties~~FD have now resolved the disagreement as detailed in the Binding 2025 MOU, pursuant to which SCYNEXIS has agreed to promptly wind-down and terminate the MARIO Study and will receive a $22 million payment from GSKDisclosure. SCYNEXIS will not receive any additional milestone payments from GSK specifically associated with the MARIO Study but will receive an additional $2.3 million payment from GSK in connection with the wind-down and termination activities.

~~GSK~~On ~~has~~March ~~reiterated~~31, ~~its~~2026, ~~commitment to continued collaboration with~~ SCYNEXIS, ~~regarding~~Inc. ~~other aspects of~~ (the ~~Exclusive~~“Company”) ~~License~~held ~~Agreement,~~a ~~including~~previously-announced ~~with~~conference ~~respect~~call to ~~the~~discuss ~~commercialization~~its ofasset ~~BREXAFEMME®~~acquisition ~~(ibrexafungerp~~transaction ~~tablets) for the vulvovaginal candidiasis (VVC)~~ and ~~refractory~~provide ~~vulvovaginal~~a ~~candidiasis~~corporate ~~(rVVC) indications~~update. ~~SCYNEXIS~~A ~~continues~~copy ~~to progress the transfer~~ of the ~~BREXAFEMME~~slide ~~NDA~~presentation toused ~~GSK~~ by the ~~end~~Company ofduring ~~2025.~~this ~~GSK~~conference ~~anticipates~~call ~~being~~is ~~able~~attached toas ~~initiate~~Exhibit ~~regulatory interactions with the U~~99.S.1 ~~Food and Drug Administration (FDA) in 2026~~ to ~~discuss~~this ~~the~~Current ~~relaunch~~Report ofon ~~BREXAFEMME~~Form ~~for~~8-K ~~VVC~~ and ~~rVVC~~incorporated ininto ~~the~~this Uitem 7.S.01 ~~market~~by reference.

~~Except~~The asfurnishing ~~described~~of ~~above~~the ~~with~~attached ~~respect~~presentation is not an admission as to the ~~MARIO~~materiality ~~Study,~~of ~~the~~any ~~Binding~~information ~~2025~~therein. ~~MOU~~The ~~does~~information ~~not~~contained ~~alter~~in the ~~potential~~slides ~~milestones~~is ~~and~~summary ~~royalties~~information ~~payable~~that is intended to ~~SCYNEXIS~~be ~~under~~considered in the ~~Exclusive~~context ~~License~~of ~~Agreement,~~more ~~including~~complete information included in the Company’s filings with ~~regard~~the toU.S. ~~sales~~Securities ofand ~~BREXAFEMME~~Exchange ~~for~~Commission ~~VVC~~(the “SEC”), and ~~rVVC~~other public announcements that the Company has made and may make from time to time by press release or otherwise.

The ~~foregoing~~information isin ~~only~~Item a7.01 ~~summary~~ of ~~the~~this ~~material~~Current ~~terms~~Report ofon ~~the~~Form ~~Binding~~8-K ~~2025~~and ~~MOU~~Exhibit 99.1 attached hereto is being “furnished” and ~~does~~will not, ~~purport~~except to bethe aextent ~~complete~~required ~~description~~by ofapplicable law or regulation, be deemed “filed” by the ~~rights~~Company ~~and~~for ~~obligations~~purposes of Section 18 of the ~~parties~~Securities ~~thereunder~~Exchange ~~and~~Act isof ~~qualified~~1934, inas ~~its~~amended, ~~entirety~~or byotherwise ~~reference~~subject to the ~~Binding~~liabilities ~~2025~~of ~~MOU~~that section, anor ~~copy~~will any of ~~which~~such ~~SCYNEXIS~~information ~~intends~~or toexhibits ~~file~~be ~~with~~deemed ~~its~~incorporated ~~Annual~~by ~~Report~~reference oninto ~~Form~~any ~~10-K~~filing ~~for~~under the ~~year~~Securities ~~ending~~Act ~~December~~of 311933, ~~2025~~as amended, ~~requesting~~or ~~confidential~~the ~~treatment~~Securities ~~for~~Exchange ~~certain~~Act ~~portions~~of ~~thereof~~1934, as amended, except as expressly set forth by specific reference in such filing.

~~SIGNATURES~~Item 9.01 Financial Statements and Exhibits.

~~Pursuant~~(d) ~~to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Exhibits.

			SCYNEXIS, Inc.
ExhibitNo.		Description
Date:	October 15, 2025	By:	/s/ David Angulo
99.1		Corporate presentation dated March 2026
		Name:Its:	David Angulo, M.D.Chief Executive Officer
104		Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCYNEXIS, Inc.

Date: March 31, 2026

/s/ David Angulo, M.D.

David Angulo, M.D.

Chief Executive Officer

Filing Compare · SCYNEXIS INC